Compares two medication approaches for adults with major depression
Compares stepwise medicines with single antidepressant use in adults with major depressive disorder.
Plain-language title generated from the registry record
Registry title: Psychopharmacotherapy for Depressive Patients
Key facts
- Where
- Gwangju, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 65 years old?
Source: NCT06054321, who can take part
Where in South Korea
- Chonnam National University HospitalGwangju, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chonnam National University Hospital
- Trial code
- NCT06054321
- Record updated
- 26 October 2026
- Original description
The primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with major depressive disorders, stratified by the multimodal serum biomarker scores.Read full original descriptionShow less
A Randomized Clinical Trial of Response to Psychopharmacotherapy According to Multimodal Serum Biomarkers in Depressive Patients
The primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with major depressive disorders, stratified by the multimodal serum biomarker scores.
Inclusion: 19 to 65 years; Diagnostic and Statistical Manual of Mental Disorders-IV criteria for major depressive disorder by study psychiatrists; Score≥17 on Hamilton Depression Rating Scale-17; With ability to understand the objective of the study and sign informed consent; Initiation of an antidepressant treatment for the current episode or no psychotropics excluding sleep pills or benzodiazepines within 1 month of participation.
Exclusion: Electroconvulsive therapy for the current depressive episode; Current or lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder not otherwise specified, or other psychotic disorders; current major depressive disorder with psychotic features; History of organic psychosis, epilepsy, or seizure disorder; Current anorexia nervosa or obsessive compulsive disorder; Unstable or uncontrolled medical condition; Unable to complete the psychiatric assessment or comply with the medication regimen due to a severe physical illness; History of anticonvulsant treatment; Hospitalization for any psychiatric diagnosis except depressive disorder (e.g., alcohol/drug dependence); severly high risk of suicide, self-harm or homicide by investigator's assessment; Pregnant or breastfeeding; lack of treatment information on the current depressive episode.